A promising new once-daily oral GLP-1 receptor agonist is generating excitement in the weight management and diabetes treatment space, offering a convenient pill alternative to injectable medications like Ozempic and Mounjaro.
Eli Lilly’s orforglipron, a small-molecule oral GLP-1 drug, has demonstrated impressive results in Phase 3 trials. In one major study (ATTAIN-1), participants taking the highest dose achieved an average weight loss of 12.4% (approximately 27.3 pounds) over 72 weeks, compared to just 0.9% in the placebo group.
In a separate head-to-head trial (ACHIEVE-3) against oral semaglutide (Rybelsus), orforglipron showed superior results:
- Greater reduction in blood sugar (A1C) levels
- Significantly more weight loss (up to 9.2% vs 5.3% for oral semaglutide)
Other Strong Contenders
- AstraZeneca’s elecoglipron also posted solid Phase 2b results, with patients losing an average of 10.5% of body weight at 26 weeks while improving blood sugar control.
- Several other oral GLP-1 candidates are advancing rapidly through clinical trials.
Why This Matters
Unlike injectable GLP-1 drugs, these new oral pills are easier to take and don’t require refrigeration or needles. Experts believe convenient oral options could dramatically increase access to effective weight-loss and diabetes treatments worldwide.
Gastrointestinal side effects (nausea, vomiting, diarrhea) remain the most common, though many patients report they improve over time with proper dose titration.
What’s Next? Eli Lilly is expected to seek regulatory approval for orforglipron in the coming months, with potential market availability as early as 2027.
This development signals a major shift toward more patient-friendly GLP-1 therapies that could help millions manage obesity and Type 2 diabetes more effectively.
